MedTrace Logo

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects

NCT05200169 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2022-01-21

No results posted yet for this study

Summary

To assess the mass balance recovery after a single oral dose of 14C-AB1010

Conditions

  • Healthy Volunteers

Interventions

DRUG

14C-AB1010

Oral solution of 14C radiolabelled AB1010 (200 mg per subject)

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Nand Singh, MD · Quotient Clinical Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-31
Primary Completion
2017-09-01
Completion
2017-09-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05200169 on ClinicalTrials.gov